Hepatit B Yüzey Antijeni (HBsAg) Pozitif Hastalarda Hepatit A ve Hepatit E Virüsü Seropozitifliği

Abstract

Introduction: In this study, we aimed to determine the anti-HAV IgG and anti-HEV IgG seroprevalence in patients admitted to our clinic with Hepatitis B surface antigen (HBsAg) positivity. 
 Material and Method: Data of 1827 patients followed up on for HBsAg positivity between 2010 and 2019 were obtained retrospectively. 
 Results: The mean age of 1827 HBsAg positive patients was 42.71±14.84; there were 730 (39.96%) female patients and 1097 (60.04%)male. Of the 923 HBsAg positive patients whose anti-HAV IgG was measured, 830(%89,9) were detected to be positive, and 93 (10.1%) negative. Anti-HAV IgG negative patients were most often in the 21-30 age range (38.7%). Age medians were significantly different between the groups (p=0.001). HBsAg positive patients who were also positive for anti-HAV IgG tended to be older than anti-HAV IgG negative patients. In contrast, there was no significant difference in gender between anti-HAV IgG negative and positive patients (p=0.674). Of 143 HBsAg positive patients who were tested for anti-HEV-IgG, five were positive (3.5%).
 Conclusion: It is of interest that we found a lower rate of anti-HAV IgG positivity in young Chronic Hepatitis B patients. When hepatitis B virus is detected, a test for anti-HAV IgG should be requested from patients and if the test result is negative, the patient should be vaccinated. Our study data analysis also revealed a low anti-HEV IgG positivity.

The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review

“…During the study period of 35 years, 111 publications were found 13–123 . Among inactive HBV carriers, 34 studies reported HDV prevalence and it did not change significantly over three decades 6,13–45 (Table 1).…”

“…(Table 2). Seventeen studies included all HBsAg‐positive patients without further describing patients' characteristics and reported decreasing (from Period 1 to Period 2, 7.0%–3.0%) and then increasing (from Period 2 to Period 3, to 4.7%) HDV prevalence 6,66–81 . Cumulative data of these three groups were taken to reveal HDV prevalence in HBV‐infected patients, and it showed decreasing (from Period 1 to Period 2) followed by increasing (from Period 2 to Period 3) HDV prevalence (Table 3 and Figure 2).…”